Medical Weight Management with GLP-1: A Thoughtful Clinical Approach

GLP-1-based treatment can be part of medical weight management for eligible patients. To understand a recommendation, it helps to separate the medicine's name, its approved use and the ongoing care around it.

What does GLP-1 mean?

GLP-1 stands for glucagon-like peptide-1, a hormone involved in appetite and blood-glucose regulation. Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at both GIP and GLP-1 receptors. These medicines are not interchangeable products, and a shared ingredient name does not make every brand, dose or formulation equivalent. Wegovy labeling and Zepbound labeling explain their respective uses.

Who may be eligible?

Weight-management indications include defined groups with obesity, or overweight with a weight-related condition. Eligibility also depends on the exact product, medical history and contraindications. A clinician should evaluate more than the number someone would like to see on the scale.

Bring details of diabetes treatment, digestive problems, previous medication reactions, pregnancy plans and other health conditions. Ask how the proposed treatment relates to the product's approved indication and which alternatives are reasonable.

What benefit is realistic?

Clinical trials have shown meaningful average weight reduction with specified medicines and lifestyle support. For example, STEP 1 studied weekly semaglutide in adults without diabetes over 68 weeks. Individual responses differed, and the result cannot be assumed for another formulation or every patient. Read the trial.

Ask which outcomes will be monitored, how tolerability will be assessed and when the clinician would reconsider the treatment. No program should promise a guaranteed target weight.

What should I ask about safety?

Discuss common adverse effects, serious warnings, interactions and reasons not to use the medicine. Request clear instructions for missed doses and symptoms requiring prompt care. A written plan is safer than adjusting treatment using advice from social media or another patient's experience.

Verify the exact product and dispensing source. Do not combine GLP-1-based medicines or change doses on your own. Follow the product’s stop-treatment instructions for warning symptoms and seek prompt medical advice. Product labeling and your clinical history should guide the decision.

Wegovy and Zepbound labeling includes contraindications for a personal or family history of medullary thyroid carcinoma, a particular thyroid cancer, or multiple endocrine neoplasia syndrome type 2, an inherited condition associated with endocrine tumors. A previous serious allergy to the prescribed product also matters. Serious adverse effects can include pancreatitis, gallbladder problems, dehydration-related kidney injury and severe allergic reactions. Persistent severe abdominal pain requires stopping treatment and prompt medical assessment under the product instructions; breathing difficulty or other signs of a serious allergic reaction require emergency care. Discuss pregnancy or pregnancy plans before treatment and follow the product-specific instructions.

What happens after weight loss?

Long-term planning matters. In a STEP 1 follow-up, participants regained substantial weight after medication and lifestyle intervention ended. This supports discussing maintenance and possible treatment changes from the beginning, without blaming a person for regain. Read the follow-up study.

For a broader view of program selection and monitoring, read the medical weight-management guide.

For a personalized discussion in Palm Beach Gardens, contact Luxe Arte Aesthetics. This article provides general education and does not replace an individual medical assessment. Treatment suitability and results vary.

Sources and further reading

• Wegovy prescribing information. Current version accessed November 3, 2026.
• Zepbound prescribing information.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183.
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564. doi:10.1111/dom.14725.